CompletedPhase 2NCT00082758
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Paul M Sondel, MD, PhD, M.D., Ph.DUniversity of Wisconsin, Madison
- Intervention
- hu14.18-Interleukin-2 fusion protein(biological)
- Enrollment
- 39 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2005 – 2012
Study locations (30)
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital Central California, Madera, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Sutter Cancer Center, Sacramento, California, United States
- UCSF Comprehensive Cancer Center, San Francisco, California, United States
- Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States
- Children's Hospital Cancer Center, Denver, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida Shands Cancer Center, Gainesville, Florida, United States
- Sacred Heart Cancer Center at Sacred Heart Hospital, Pensacola, Florida, United States
- St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States
- Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States
- MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00082758 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University